Clinical and Medical Engineering Live
ISSN: 2997-612X | DOI: 10.64030/2997-612X
Kennet Patrik, Fenella Chadwick
This case report illustrates the transformative potential of personalized medicine through the application of targeted therapy guided by comprehensive genomic sequencing in a patient with metastatic melanoma. A 62-year-old male with stage IV melanoma, refractory to initial immunotherapy, underwent next-generation sequencing (NGS) of a tumor biopsy. The analysis revealed a BRAF V600E mutation and co-occurring alterations in CDKN2A and TERT. Based on the BRAF mutation, the patient was initiated on a combination of dabrafenib and trametinib, resulting in a significant and rapid partial response, sustained over 18 months with manageable toxicities. This case highlights the critical role of genomic profiling in identifying actionable mutations and tailoring treatment strategies, leading to improved clinical outcomes in patients with advanced cancers.